The National Institute on Drug Abuse has awarded nearly $2.3 million to Brigham and Women's Hospital in Boston to test whether ibogaine, a psychedelic from the African iboga shrub, can be given safely to people with opioid use disorder, according to federal grant records. The study's design puts the drug's best-known danger front and center: any dose that stretches the heart's electrical recovery time past a set limit will be treated as too toxic.
Interest in ibogaine is climbing, driven by an April executive order on psychedelic research, new state funding, and veterans' accounts of treatment abroad. But ibogaine remains a Schedule I drug with no accepted medical use in the United States, and no FDA-approved form exists.
For families with a loved one in recovery, the most urgent point is straightforward. Proven medications for opioid use disorder, including buprenorphine and methadone, remain the standard of care, and stopping them to pursue an unproven treatment can raise overdose risk.
Grant Details and a Cautious Trial Plan
The cooperative agreement runs from June 2026 through May 2028, with $2,288,947 awarded so far. Psychedelic Alpha reported that the project could reach about $11 million if it advances, with psychiatrist Dr. Joji Suzuki of Mass General Brigham leading the work.
The team must first secure FDA clearance to study ibogaine under an investigational new drug application without a clinical hold. Only then would a Phase 1 study begin, giving single, rising doses of pharmaceutical-grade ibogaine to healthy volunteers to find the highest tolerable dose.
The grant abstract defines a dose as too toxic if a participant's QTc interval, a measure of how long the heart takes to reset between beats, exceeds 500 milliseconds or rises by 20%. Dosing would happen during an inpatient hospital stay with ECG monitoring, similar to how hospitals start certain heart rhythm drugs such as sotalol and dofetilide.
If Phase 1 succeeds, a Phase 2a trial would enroll people with opioid use disorder who are not responding adequately to buprenorphine. That stage would compare doses, use blinded assessors, and include only people who have never taken ibogaine.
The researchers wrote that they know of no other rigorous study planned under an FDA investigational new drug application to test ibogaine itself for opioid use disorder. Results from either phase are likely years away, and the timeline depends on the FDA agreeing to each step. A separate federal research agency, ARPA-H, also opened a funding opportunity this summer aimed at developing ibogaine for opioid use disorder, Psychedelic Alpha reported.
Heart Rhythm Risk Shapes Every Step
Ibogaine can lengthen the QT interval, which can trigger a dangerous heart rhythm and sudden cardiac arrest. Deaths have been linked to its use outside clinical trials, and addiction specialists have described irregular heart rhythm as the biggest danger, particularly in people who have been taking long-acting opioids, MindSite News reported in 2024.
The FDA has taken a narrower step with a related compound. In April, it allowed an early-stage U.S. study of noribogaine, ibogaine's main metabolite, as a potential treatment for alcohol use disorder, the first time the agency has allowed a U.S. clinical study of an ibogaine derivative. The agency stressed that the decision "does not mean the drug has been approved or found to be safe or effective," according to its announcement.
An April 18 executive order directed federal agencies to speed the development and review of psychedelic therapies, including ibogaine-related compounds. States are also funding research, and MedicalDaily reported on Arizona's $5 million ibogaine trial in brain injury.
Families Weighing Clinics Abroad
Many Americans seeking ibogaine travel to clinics in Mexico, where the treatment is unregulated. Patients at one clinic near Tijuana pay around $8,000, The War Horse has reported, and medical screening, heart monitoring, and emergency readiness vary from clinic to clinic.
Addiction physicians have flagged a quieter danger. An editorial in the Journal of Addiction Medicine cautioned that some proponents frame ibogaine as a replacement for, rather than a complement to, medications that lower the risk of death. Detoxing from methadone or buprenorphine in favor of an unproven therapy could increase overdose risk for some people, the authors wrote.
The people at highest risk from ibogaine include those with heart disease, a personal or family history of long QT syndrome or unexplained fainting, and anyone taking other drugs that prolong the QT interval. The Brigham grant abstract itself notes that methadone is one such drug.
Families can ask a clinician about adjusting buprenorphine dosing, switching to methadone or a long-acting formulation, or adding counseling before considering experimental options. Anyone who has taken ibogaine and develops fainting, a racing or irregular heartbeat, chest pain, or a seizure needs emergency care. Treatment referrals are available through the SAMHSA National Helpline at 1-800-662-4357, and anyone in crisis can call or text 988.
The next milestone is the FDA's response to the team's investigational application. Until regulators clear and researchers complete these trials, no one can say whether ibogaine's benefits outweigh its heart risks. MedicalDaily will report on the study's regulatory status as new federal records and announcements become available.
Key Questions Answered
What did NIH fund?
A NIDA cooperative agreement of about $2.3 million in its first year to Brigham and Women's Hospital to study ibogaine's safety and early effectiveness for opioid use disorder.
Is ibogaine legal or approved?
No. It is a Schedule I drug in the United States, and the FDA has not approved any ibogaine product.
Why is the heart such a concern?
Ibogaine can lengthen the QT interval, which can trigger dangerous heart rhythms and sudden cardiac arrest.
How will the study protect participants?
Dosing would happen in a hospital with ECG monitoring, and a dose counts as too toxic if QTc exceeds 500 milliseconds or rises by 20%.
Who would eventually be enrolled?
Healthy volunteers first, then people with opioid use disorder who are not responding adequately to buprenorphine.
Should someone stop buprenorphine or methadone to try ibogaine?
Not without a clinician. Addiction physicians warn that stopping proven medications for an unproven therapy can raise overdose risk.
Where can families get help now?
The SAMHSA National Helpline at 1-800-662-4357 offers treatment referrals, and 988 is available for anyone in crisis.
